Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway
Open Access
- 10 June 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cellular & Molecular Immunology
- Vol. 18 (5), 1278-1289
- https://doi.org/10.1038/s41423-020-0444-5
Abstract
Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist to inhibit platelet activation and has been approved by the Food and Drug Administration for the treatment of coronary artery disease. At present, the other pharmacological functions of ticagrelor remain poorly understood. The NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome plays a critical role in the innate immune system, but its excessive activation also contributes to the pathogenesis of complex diseases. In this study, we systematically examined the effects of ticagrelor on the NLRP3 inflammasome and found that ticagrelor inhibits NLRP3 inflammasome activation in macrophages independent of its classic inhibitory effect on the P2Y12 signaling pathway. Further mechanistic studies demonstrate that ticagrelor attenuates the oligomerization of apoptosis-associated speck-like protein containing a CARD (ASC) by blocking chloride efflux, an effect achieved through the degradation of chloride intracellular channel proteins (CLICs) and blockade of the translocation of CLICs to the plasma membrane. Moreover, experiments on lipopolysaccharide-induced sepsis and alum-induced peritonitis in mice confirmed that ticagrelor mitigates the severity of systemic inflammation independent of P2Y12 receptor antagonism. Importantly, oral administration of ticagrelor rapidly and strongly inhibited NLRP3 inflammasome activation in peripheral blood mononuclear cells from patients with acute coronary syndrome. Overall, our study reveals a novel pharmacological function of ticagrelor in addition to its classic antiplatelet properties, which suggests that ticagrelor may serve as a potential therapeutic agent for use in NLRP3-associated diseases.Funding Information
- National Natural Science Foundation of China (81773016, 21976155, 31471297)
This publication has 54 references indexed in Scilit:
- The Inflammasome NLRs in Immunity, Inflammation, and Associated DiseasesAnnual Review of Immunology, 2011
- The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defectsBlood, 2011
- Sterile inflammation: sensing and reacting to damageNature Reviews Immunology, 2010
- Autocrine Purinergic Receptor Signaling Is Essential for Macrophage ChemotaxisScience Signaling, 2010
- Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense againstSalmonellaThe Journal of Experimental Medicine, 2010
- The InflammasomesCell, 2010
- The enigma of the CLIC proteins: Ion channels, redox proteins, enzymes, scaffolding proteins?FEBS Letters, 2010
- Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 ExpressionThe Journal of Immunology, 2009
- AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASCNature, 2009
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005